Usefulness of the PARIS Score to Evaluate the Ischemic-hemorrhagic Net Benefit With Ticagrelor and Prasugrel After an Acute Coronary Syndrome.
Raposeiras-Roubín S, Caneiro Queija B, D'Ascenzo F, Kinnaird T, Ariza-Solé A, Manzano-Fernández S, Templin C, Velicki L, Xanthopoulou I, Cerrato E, Quadri G, Rognoni A, Boccuzzi G, Montabone A, Taha S, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Flores Blanco P, Garay A, Varbella F, Tomassini F, Cobas Paz R, Cespón Fernández M, Muñoz Pousa I, Gallo D, Morbiducci U, Domínguez-Rodríguez A, Baz-Alonso JA, Calvo-Iglesias F, Valdés M, Cequier Á, Gaita F, Alexopoulos D, Íñiguez-Romo A, Abu-Assi E.
Raposeiras-Roubín S, et al. Among authors: gili s.
Rev Esp Cardiol (Engl Ed). 2019 Mar;72(3):215-223. doi: 10.1016/j.rec.2018.06.004. Epub 2018 Jul 18.
Rev Esp Cardiol (Engl Ed). 2019.
PMID: 30029980
English, Spanish.